Sellas Life Sciences Group Inc
Follow $SLS
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $SLS by emailVeridion Score
BETALOW CONF · 4 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is SLS moving today?
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
SLS overview
Related filings and maps
Congress activity in SLS
No receipt-qualified Congressional disclosure is present for SLS in the cached public ledger.
SLS contract awards, year to date.
Public federal awards linked to this ticker.
SLS lobbying filings, year to date.
Registered lobbying filings matched to Sellas Life Sciences Group Inc.